Rodatristat ethyl (KAR5585) is a first-in-class oraltryptophan hydroxylase1 (TPH1)Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of5-HTand significantly reduces pulmonary arterial hypertension (PAH)^[1][2].

Rodatristat ethyl (100 or 200 mg/kg; oral administration; once daily; for 28 days; male Sprague-Dawley rats) treatment decreases erum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduces pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats with monocrotaline (MCT)^[1].

590.04

C₂₉H₃₁ClF₃N₅O₃

1673571-51-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.